Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
85.4 GBX | -0.52% | +6.02% | -3.61% |
May. 21 | Marathon Partners Calls for Specifics of Dr. Martens' Cost-cutting, Buyback Plans | MT |
May. 20 | Marathon Partners Urges Dr. Martens to Buy Back Stock | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company is one of the best yield companies with high dividend expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Footwear
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.61% | 1.05B | C+ | ||
+32.05% | 11.12B | C+ | ||
+8.08% | 10.35B | C | ||
-5.01% | 8.7B | - | ||
+52.68% | 8.59B | B- | ||
-4.49% | 8.08B | A- | ||
+21.68% | 3.49B | A- | ||
+78.47% | 3.2B | B- | ||
-8.20% | 2.49B | C | ||
-17.91% | 2.11B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DOCS Stock
- Ratings Dr. Martens plc